A Phase IIa clinical trial testing Structure Therapeutics, Inc.’s oral GLP-1 receptor agonist GSBR-1290 in patients with type 2 diabetes met the primary safety and tolerability endpoints and showed a statistically significant reduction in hemoglobin A1c and weight at week 12, but investors were hoping to see stronger efficacy results.
Key Takeaways
- A Phase IIa clinical trial testing Structure Therapeutics Inc.’s oral GLP-1 receptor agonist GSBR-1290 was positive for safety and efficacy.
Structure’s stock price tumbled 46% after the company announced the news, opening 18 December at $31.90, despite positive results. CEO...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?